News ESMO26: AZ's claudin ADC doubles survival in GI cancers AstraZeneca's CLARITY-Gastric01 trial of sone-ve in CLDN18.2-positive gastrointestinal cancers reveals a 53% reduction in the risk of death.
News ESMO26: Takeda preps filings on CLDN18.2 gastric cancer data Takeda and Innovent's CLDN18.2-targeting ADC, arcotatug tavatecan, will be filed in Japan on the back of positive survival data in gastric cancer.
News Ultomiris fail mars AZ's strong Q2 results AstraZeneca has served up a robust set of interim results, leavened by strong sales of cancer drugs, but with some mixed pipeline news on the side.
News CARSgen bags world-first approval for solid tumour CAR-T CARSgen Therapeutics has claimed approval in China for gastric cancer therapy satri-cel, the first CAR-T to be cleared for a solid tumour.
News NICE backs stomach cancer, PAH drugs for NHS use AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.
News AZ piles pressure on MSD et al in gastric cancer AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage gastric cancer.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.